
Annabel Samimy
Stock Analyst at Stifel Nicolaus
(4.82)
# 497
Out of 5,162 analysts
383
Total ratings
50%
Success rate
15.9%
Average return
Main Sectors:
Stocks Rated by Annabel Samimy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EYPT EyePoint | Reiterated: Buy | $6 → $5 | $0.2642 | +1,792.51% | 3 | Nov 13, 2026 | |
| GPCR Structure Therapeutics | Reiterated: Buy | $90 | $17.12 | +425.70% | 10 | Nov 10, 2026 | |
| MBX MBX Biosciences | Reiterated: Buy | $84 | $53.41 | +57.27% | 13 | Nov 10, 2026 | |
| TRVI Trevi Therapeutics | Reiterated: Buy | $30 | $13.72 | +118.66% | 26 | Nov 10, 2026 | |
| TLV: KMDA Kamada Ltd. | Reiterated: Buy | ILA 3,831 | ILA 2,610 | +46.78% | 4 | Nov 9, 2026 | |
| EOLS Evolus | Reiterated: Buy | $17 | $7.00 | +142.86% | 28 | Nov 5, 2026 | |
| MLYS Mineralys Therapeutics | Reiterated: Buy | $52 | $14.16 | +267.23% | 14 | Nov 5, 2026 | |
| OCS Oculis Holding AG | Reiterated: Buy | $40 | $7.44 | +437.63% | 14 | Nov 4, 2026 | |
| SUPN Supernus | Reiterated: Hold | $37 | $28.35 | +30.51% | 1 | Nov 4, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $275 | $236.45 | +16.30% | 43 | Nov 3, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $350 | $286.94 | +21.98% | 11 | Oct 30, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $95 | $25.84 | +267.65% | 27 | Oct 29, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $42 | $7.18 | +484.96% | 28 | Oct 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $35.77 | $8.78 | +307.37% | 5 | Sep 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $3.45 | +334.78% | 20 | Sep 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $250 | $145.77 | +71.50% | 9 | Jun 24, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $28 | $5.08 | +451.18% | 6 | Jan 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $1.41 | - | 7 | Dec 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $0.5806 | n/a | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.9461 | n/a | 19 | Dec 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 | $1.83 | n/a | 13 | Aug 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21.46 → $20.03 | $12.30 | n/a | 24 | Nov 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $5 → $15 | $1.50 | n/a | 4 | Jun 30, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $5 | $1.81 | n/a | 20 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $80 → $87 | $16.04 | n/a | 14 | Aug 9, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $7 | $6.26 | n/a | 8 | Nov 7, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $64.98 | n/a | 1 | Jan 13, 2014 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $27 | $7.60 | n/a | 1 | Dec 4, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $56 | $31.73 | n/a | 1 | Oct 18, 2011 |
EyePoint
Nov 13, 2026
Reiterated: Buy
Price Target: $6 → $5
Current: $0.2642
Upside: +1,792.51%
Structure Therapeutics
Nov 10, 2026
Reiterated: Buy
Price Target: $90
Current: $17.12
Upside: +425.70%
MBX Biosciences
Nov 10, 2026
Reiterated: Buy
Price Target: $84
Current: $53.41
Upside: +57.27%
Trevi Therapeutics
Nov 10, 2026
Reiterated: Buy
Price Target: $30
Current: $13.72
Upside: +118.66%
Kamada Ltd.
Nov 9, 2026
Reiterated: Buy
Price Target: ILA 3,831
Current: ILA 2,610
Upside: +46.78%
Evolus
Nov 5, 2026
Reiterated: Buy
Price Target: $17
Current: $7.00
Upside: +142.86%
Mineralys Therapeutics
Nov 5, 2026
Reiterated: Buy
Price Target: $52
Current: $14.16
Upside: +267.23%
Oculis Holding AG
Nov 4, 2026
Reiterated: Buy
Price Target: $40
Current: $7.44
Upside: +437.63%
Supernus
Nov 4, 2026
Reiterated: Hold
Price Target: $37
Current: $28.35
Upside: +30.51%
Jazz Pharmaceuticals
Nov 3, 2026
Reiterated: Buy
Price Target: $275
Current: $236.45
Upside: +16.30%
Oct 30, 2026
Reiterated: Buy
Price Target: $350
Current: $286.94
Upside: +21.98%
Oct 29, 2026
Reiterated: Buy
Price Target: $95
Current: $25.84
Upside: +267.65%
Oct 21, 2026
Reiterated: Buy
Price Target: $42
Current: $7.18
Upside: +484.96%
Sep 24, 2026
Reiterated: Buy
Price Target: $35.77
Current: $8.78
Upside: +307.37%
Sep 23, 2026
Reiterated: Buy
Price Target: $15
Current: $3.45
Upside: +334.78%
Jun 24, 2026
Reiterated: Buy
Price Target: $250
Current: $145.77
Upside: +71.50%
Jan 15, 2026
Reiterated: Buy
Price Target: $28
Current: $5.08
Upside: +451.18%
Dec 19, 2025
Reiterated: Buy
Price Target: n/a
Current: $1.41
Upside: -
Apr 1, 2025
Reiterated: Buy
Price Target: $8
Current: $0.5806
Upside: n/a
Dec 19, 2024
Rated: Hold
Price Target: n/a
Current: $0.9461
Upside: n/a
Aug 30, 2023
Reiterated: Hold
Price Target: $11
Current: $1.83
Upside: n/a
Nov 3, 2022
Reiterated: Buy
Price Target: $21.46 → $20.03
Current: $12.30
Upside: n/a
Jun 30, 2022
Downgraded: Hold
Price Target: $5 → $15
Current: $1.50
Upside: n/a
May 6, 2021
Reiterated: Buy
Price Target: $6 → $5
Current: $1.81
Upside: n/a
Aug 9, 2018
Reiterated: Hold
Price Target: $80 → $87
Current: $16.04
Upside: n/a
Nov 7, 2016
Reiterated: Hold
Price Target: $7
Current: $6.26
Upside: n/a
Jan 13, 2014
Downgraded: Hold
Price Target: n/a
Current: $64.98
Upside: n/a
Dec 4, 2013
Initiated Coverage: Buy
Price Target: $27
Current: $7.60
Upside: n/a
Oct 18, 2011
Rated: Buy
Price Target: $56
Current: $31.73
Upside: n/a